NASDAQ:NBIX Neurocrine Biosciences (NBIX) Stock Forecast, Price & News $92.32 +1.13 (+1.24%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$90.54▼$92.5350-Day Range$89.53▼$104.8752-Week Range$88.38▼$129.29Volume422,520 shsAverage Volume713,093 shsMarket Capitalization$9.01 billionP/E Ratio153.87Dividend YieldN/APrice Target$125.21 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Neurocrine Biosciences MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside35.6% Upside$125.21 Price TargetShort InterestBearish2.86% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment0.96Based on 6 Articles This WeekInsider TradingSelling Shares$3.84 M Sold Last QuarterProj. Earnings Growth156.04%From $1.82 to $4.66 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.64 out of 5 starsMedical Sector82nd out of 983 stocksBiological Products, Except Diagnostic Industry12th out of 164 stocks 4.4 Analyst's Opinion Consensus RatingNeurocrine Biosciences has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 12 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $125.21, Neurocrine Biosciences has a forecasted upside of 35.6% from its current price of $92.32.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.86% of the outstanding shares of Neurocrine Biosciences have been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Neurocrine Biosciences has recently increased by 5.68%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. Previous Next 2.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNeurocrine Biosciences has received a 24.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Valbenazine", "Elagolix", and "Opicapone" products. See details.Environmental SustainabilityThe Environmental Impact score for Neurocrine Biosciences is -2.61. Previous Next 2.2 News and Social Media Coverage News SentimentNeurocrine Biosciences has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Neurocrine Biosciences this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for NBIX on MarketBeat in the last 30 days. This is a decrease of -97% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,838,922.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions92.58% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 156.04% in the coming year, from $1.82 to $4.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 153.87, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 120.56.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 153.87, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 70.52.Price to Earnings Growth RatioNeurocrine Biosciences has a PEG Ratio of 1.13. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 5.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Neurocrine Biosciences (NASDAQ:NBIX) StockNeurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops, and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.Read More Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Stock News HeadlinesJune 4, 2023 | americanbankingnews.comComparing Krystal Biotech (NASDAQ:KRYS) and Neurocrine Biosciences (NASDAQ:NBIX)June 2, 2023 | finance.yahoo.comNeurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress ElevateJune 4, 2023 | Chaikin Analytics (Ad)Famous Wall Street Crash System Flashes REDHundreds of banks, hedge funds, and brokerages have paid $5,000 a month to access these alerts. Because when this system flashes on U.S. stocks, huge gains – and losses – can follow.May 31, 2023 | americanbankingnews.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Rating of "Moderate Buy" from BrokeragesMay 24, 2023 | seekingalpha.comNeurocrine Biosciences: In Limbo Until The Arrival Of The 'Next Big Thing' Beyond IngrezzaMay 19, 2023 | finance.yahoo.comAre Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?May 18, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Neurocrine Biosciences (NASDAQ:NBIX)May 15, 2023 | finance.yahoo.comNeurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Society 2023 Annual CongressJune 4, 2023 | MarketBeat Internal (Ad)Introducing MarketBeat All AccessGet real-time financial news and market data with MarketBeat All Access. Monitor your portfolio and the markets. Access our top stock picks, unbeatable research tools, best-in-class stock screeners, and proprietary research reports.May 12, 2023 | finance.yahoo.comNeurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023May 10, 2023 | americanbankingnews.comHC Wainwright Brokers Cut Earnings Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX)May 9, 2023 | americanbankingnews.comWilliam Blair Weighs in on Neurocrine Biosciences, Inc.'s Q3 2023 Earnings (NASDAQ:NBIX)May 9, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Cut by SVB LeerinkMay 9, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Neurocrine Biosciences, Inc. Lowered by Wedbush (NASDAQ:NBIX)May 7, 2023 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Rating Increased to Buy at GuggenheimMay 6, 2023 | benzinga.comBoard Member at Neurocrine Biosciences Exercises Options Worth $751KMay 6, 2023 | americanbankingnews.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 4,300 Shares of StockMay 5, 2023 | americanbankingnews.comResearch Analysts Set Expectations for Neurocrine Biosciences, Inc.'s Q1 2023 Earnings (NASDAQ:NBIX)May 4, 2023 | msn.comGuggenheim Upgrades Neurocrine Biosciences (NBIX)May 4, 2023 | markets.businessinsider.comNeurocrine (NBIX) Gets a Hold from Mizuho SecuritiesMay 4, 2023 | msn.comBarclays Maintains Neurocrine Biosciences (NBIX) Overweight RecommendationMay 4, 2023 | msn.comWells Fargo Maintains Neurocrine Biosciences (NBIX) Equal-Weight RecommendationMay 4, 2023 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Cut to $111.00 by Analysts at MizuhoMay 4, 2023 | americanbankingnews.comCitigroup Lowers Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $122.00May 4, 2023 | americanbankingnews.comBarclays Lowers Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $125.00May 4, 2023 | americanbankingnews.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $1,184,034.33 in StockMay 4, 2023 | americanbankingnews.comBrokerages Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) PT at $125.00See More Headlines NBIX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBIX Company Calendar Last Earnings2/06/2023Today6/04/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NBIX CUSIP64125C10 CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees1,200Year FoundedN/APrice Target and Rating Average Stock Price Forecast$125.21 High Stock Price Forecast$150.00 Low Stock Price Forecast$95.00 Forecasted Upside/Downside+35.6%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)$0.60 Trailing P/E Ratio153.87 Forward P/E Ratio50.73 P/E Growth1.12Net Income$154.50 million Net Margins4.00% Pretax Margin5.58% Return on Equity4.03% Return on Assets2.88% Debt Debt-to-Equity Ratio0.10 Current Ratio3.83 Quick Ratio3.74 Sales & Book Value Annual Sales$1.49 billion Price / Sales6.05 Cash Flow$1.80 per share Price / Cash Flow51.18 Book Value$17.26 per share Price / Book5.35Miscellaneous Outstanding Shares97,570,000Free Float93,282,000Market Cap$9.01 billion OptionableOptionable Beta0.48 Key ExecutivesKevin Charles GormanChief Executive Officer & DirectorBill WilsonVice President-Information Technology & OperationsMatthew C. AbernethyChief Financial OfficerDimitri E. GrigoriadisChief Research OfficerEiry W. RobertsChief Medical OfficerKey CompetitorsRepligenNASDAQ:RGENExelixisNASDAQ:EXELHalozyme TherapeuticsNASDAQ:HALOQiagenNYSE:QGENCRISPR TherapeuticsNASDAQ:CRSPView All CompetitorsInsiders & InstitutionsMacquarie Group Ltd.Bought 7,296 shares on 6/1/2023Ownership: 0.300%ProShare Advisors LLCSold 2,889 shares on 5/26/2023Ownership: 0.013%Toroso Investments LLCBought 2,057 shares on 5/23/2023Ownership: 0.002%Ameriprise Financial Inc.Sold 57,776 shares on 5/22/2023Ownership: 0.559%American TrustSold 2,610 shares on 5/22/2023Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions NBIX Stock - Frequently Asked Questions Should I buy or sell Neurocrine Biosciences stock right now? 17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 5 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NBIX shares. View NBIX analyst ratings or view top-rated stocks. What is Neurocrine Biosciences' stock price forecast for 2023? 17 Wall Street research analysts have issued twelve-month price targets for Neurocrine Biosciences' stock. Their NBIX share price forecasts range from $95.00 to $150.00. On average, they predict the company's share price to reach $125.21 in the next year. This suggests a possible upside of 35.6% from the stock's current price. View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts. How have NBIX shares performed in 2023? Neurocrine Biosciences' stock was trading at $119.44 at the beginning of 2023. Since then, NBIX shares have decreased by 22.7% and is now trading at $92.32. View the best growth stocks for 2023 here. When is Neurocrine Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our NBIX earnings forecast. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its quarterly earnings data on Monday, February, 6th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.15 by $0.09. The firm earned $412 million during the quarter, compared to analysts' expectations of $408.96 million. Neurocrine Biosciences had a trailing twelve-month return on equity of 4.03% and a net margin of 4.00%. Neurocrine Biosciences's revenue for the quarter was up 32.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.08) earnings per share. What ETFs hold Neurocrine Biosciences' stock? ETFs with the largest weight of Neurocrine Biosciences (NASDAQ:NBIX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Biotechnology & Genome ETF (PBE), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco S&P MidCap Momentum ETF (XMMO), Invesco S&P MidCap 400 Pure Growth ETF (RFG), Roc Etf (ROCI) and Virtus LifeSci Biotech Products ETF (BBP). What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO? 11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM). What is Neurocrine Biosciences' stock symbol? Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX." Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.80%), State Street Corp (3.89%), Renaissance Technologies LLC (2.00%), Bank of New York Mellon Corp (1.69%), Armistice Capital LLC (1.63%) and Geode Capital Management LLC (1.47%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Neurocrine Biosciences' stock price today? One share of NBIX stock can currently be purchased for approximately $92.32. How much money does Neurocrine Biosciences make? Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $9.01 billion and generates $1.49 billion in revenue each year. The company earns $154.50 million in net income (profit) each year or $0.60 on an earnings per share basis. How many employees does Neurocrine Biosciences have? The company employs 1,200 workers across the globe. How can I contact Neurocrine Biosciences? Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for the company is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at ir@neurocrine.com, or via fax at 858-617-7602. This page (NASDAQ:NBIX) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.